Target Name: MDFIC
NCBI ID: G29969
Review Report on MDFIC Target / Biomarker Content of Review Report on MDFIC Target / Biomarker
MDFIC
Other Name(s): MyoD family inhibitor domain containing, transcript variant 1 | LMPHM12 | OTTHUMP00000025265 | MyoD family inhibitor domain-containing protein (isoform p40) | MDFIC1 | MyoD family inhibitor domain-containing protein | MyoD family inhibitor domain-containing protein (isoform p32) | OTTHUMP00000206391 | HIC | hIC | MDFIC variant 1 | MDFIC_HUMAN | I-mfa domain-containing protein | OTTHUMP00000220850 | MyoD family inhibitor domain containing

MDFIC: A Potential Drug Target and Biomarker for Muscle Development and Function

MyoD family inhibitor domain containing protein (MDFIC) is a protein that plays an important role in muscle development and function. It is a non-coding RNA molecule that is expressed in a variety of tissues, including muscle fibers, heart muscle, and the brain . MDFIC has been shown to be involved in the regulation of muscle growth, contraction, and differentiation. In addition, MDFIC has also been shown to be involved in the regulation of cell survival and proliferation.

The MDFIC gene
The MDFIC gene is located on chromosome 22 and has a length of approximately 1,300 base pairs. It is a member of the myodysplastic gene family, which is characterized by the presence of a myodysplastic domain in the protein coding region. The myodysplastic domain is a unique region of the protein that is involved in the regulation of cell growth and differentiation.

MDFIC function
MDFIC is involved in the regulation of muscle development and function by promoting the growth and maintenance of muscle fibers. It does this by inhibiting the activity of several transcription factors, including MyoD, which is a protein that is involved in the regulation of muscle growth and development.

In addition to its role in muscle development, MDFIC is also involved in the regulation of cell survival and proliferation. It has been shown to play a role in the regulation of cell apoptosis, which is the process by which cells undergo programmed cell death. This is done by inhibiting the activity of several proteins that are involved in cell apoptosis, including Bax, which is a protein that is involved in the regulation of cell death.

MDFIC as a drug target
MDFIC is a protein that is involved in the regulation of muscle development and function, as well as cell survival and proliferation. As a result, it is a potential drug target for the treatment of a variety of muscle-related conditions, including muscle dystrophy, myopathies, and cancer.

One potential approach to targeting MDFIC is to use small molecules to inhibit its activity. This can be done by identifying compounds that are able to bind to specific regions of MDFIC and prevent it from interacting with its target proteins. This can be done using a variety of techniques, including high-throughput screening and virtual screening.

Another approach to targeting MDFIC is to use antibodies to block its activity. This can be done by identifying antibodies that are able to bind to specific regions of MDFIC and prevent it from interacting with its target proteins. This can be done using a variety of techniques , including immunization with antibodies and capture with affinity columns.

MDFIC as a biomarker
MDFIC is also potential biomarker for some diseases. For example, MDFIC has been shown to be downregulated in muscle samples from patients with dystrophy diseases, such as dystrophin-deficient syndrome (DSS). Additionally, MDFIC has been shown to be upregulated in muscle samples from patients with cancer, which may indicate that it is a potential biomarker for cancer.

Conclusion
MDFIC is a non-coding RNA molecule that is involved in the regulation of muscle development and function, as well as cell survival and proliferation. It is a potential drug target and biomarker for a variety of muscle-related conditions, including muscle dystrophy and cancer . Further research is needed to fully understand the role of MDFIC in muscle development and function, as well as its potential as a drug and biomarker.

Protein Name: MyoD Family Inhibitor Domain Containing

Functions: Required to control the activity of various transcription factors through their sequestration in the cytoplasm. Retains nuclear Zic proteins ZIC1, ZIC2 and ZIC3 in the cytoplasm and inhibits their transcriptional activation (By similarity). Modulates the expression from both cellular and viral promoters. Down-regulates Tat-dependent transcription of the human immunodeficiency virus type 1 (HIV-1) LTR by interacting with HIV-1 Tat and Rev and impairing their nuclear import, probably by rendering the NLS domains inaccessible to importin-beta (PubMed:16260749, PubMed:12944466, Ref.6). Also stimulates activation of human T-cell leukemia virus type I (HTLV-I) LTR (PubMed:10671520). Binds to the axin complex, resulting in an increase in the level of free beta-catenin (PubMed:12192039). Affects axin regulation of the WNT and JNK signaling pathways (PubMed:12192039). Has a role in the development of lymphatic vessel valves. It is required to promote lymphatic endothelial cell migration, in a process that involves down-regulation of integrin beta 1 activation and control of cell adhesion to the extracellular matrix (PubMed:35235341) (By similarity)

The "MDFIC Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MDFIC comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MDGA1 | MDGA2 | MDH1 | MDH1B | MDH2 | MDK | MDM1 | MDM2 | MDM4 | MDN1 | MDS2 | ME1 | ME2 | ME3 | MEA1 | MEAF6 | MEAF6P1 | MEAK7 | Mechanoelectrical transducer (MET) channel | Mechanosensitive Ion Channel | MECOM | MECOM-AS1 | MeCP1 histone deacetylase (HDAC) complex | MECP2 | MECR | MED1 | MED10 | MED11 | MED12 | MED12L | MED13 | MED13L | MED14 | MED14P1 | MED15 | MED15P8 | MED16 | MED17 | MED18 | MED19 | MED20 | MED21 | MED22 | MED23 | MED24 | MED25 | MED26 | MED27 | MED28 | MED29 | MED30 | MED31 | MED4 | MED4-AS1 | MED6 | MED7 | MED8 | MED9 | MEDAG | Mediator Complex | Mediator of RNA Polymerase II Transcription | MEF2A | MEF2B | MEF2C | MEF2C-AS1 | MEF2C-AS2 | MEF2D | MEFV | MEG3 | MEG8 | MEG9 | MEGF10 | MEGF11 | MEGF6 | MEGF8 | MEGF9 | MEI1 | MEI4 | MEIG1 | MEIKIN | MEIOB | MEIOC | MEIOSIN | MEIS1 | MEIS1-AS2 | MEIS1-AS3 | MEIS2 | MEIS3 | MEIS3P1 | MEIS3P2 | Melanin | Melanin-concentrating hormone (MCH) receptor | Melanocortin receptor | Melanoma-Associated Antigen | Melatonin receptor | MELK | MELTF | MELTF-AS1 | Membrane-Bound Protein Tyrosine Phosphatases (rPTPs) | Membrane-spanning 4-domains subfamily A member 4A